The alanine-serine-cysteine transporter Asc-1 regulates the synaptic availability of d-serine and glycine (the two co-agonists of the NMDA receptor) and is regarded as an important drug target. To shuttle the substrate from the extracellular space to the cytoplasm, this transporter undergoes multiple distinct conformational states. In this work, homology modeling, substrate docking and molecular dynamics simulations were carried out to learn more about the transition between the "outwardopen" and "outward-open occluded" states. We identified a transition state involving the highlyconserved unwound TM6 region in which the Phe243 flips close to the d-serine substrate without major movements of TM6. This feature and those of other key residues are proposed to control the binding site and substrate translocation. Competitive inhibitors ACPP, LuAE00527 and SMLC were docked and their binding modes at the substrate binding site corroborated the key role played by Phe243 of TM6. For ACPP and LuAE00527, strong hydrophobic interactions with this residue hinder its mobility and prevent the uptake and the efflux of substrates. As for SMLC, the weaker interactions maintain the flexibility of Phe243 and the efflux process. Overall, we propose a molecular basis for the inhibition of substrate translocation of the Asc-1 transporter that should be valuable for rational drug design.The alanine-serine-cysteine transporter (referred to as SLC7A10 or Asc-1) is the light chain of the heterodimer amino acid transporter (HAT), and is a Na + -independent antiporter distributed throughout the central nervous system (CNS). Asc-1 is present at both astrocytes and neurons 1-3 , and displays high affinity for neutral amino acids and uses diverse substrates, such as l-serine, l-alanine, l-cysteine along with glycine and d-serine 4 . However, glycine and d-serine serve as two necessary and positive allosteric modulators of the N-methyl-d-aspartate (NMDA) subtype of glutamate receptors, and bind to the strychnine insensitive binding site (referred to as the 'glycine site') of those receptors (Fig. 1a) 5,6 . For these reasons, Asc-1 is a promising druggable target relevant for treating cognitive affections during normal or pathological aging but also in disorders like schizophrenia 7-12 . Indeed, Asc-1 primarily mediates the efflux of d-serine and glycine through the hetero-exchange with other neutral amino acids, and thus regulates glutamatergic neurotransmission and synaptic plasticity in the forebrain 13 . But, recent studies suggest that Asc-1 is also involved in the control of glycinergic transmission in the caudal brain and spinal cord 2,3,14 . SLC7a10-null mice display reduced levels of glycine, but not d-serine, and show rigidity and myoclonus characteristic of the clinical condition called hyperekplexia 2,14 .Given the important physiological function of Asc-1 in regulating d-serine and glycine levels, modulating Asc-1 function could provide therapeutical benefits for alleviating the symptoms caused notably by the hypofunction of NMDARs ...